← Leaderboards
Ali Rayet Ozes
Altay Therapeutics, Inc.
$1,298,527
Attributed
$1,298,527
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $998.5K · FY2022–24$1M$750K$500K$250K$0
'22
'23
'24
Funding mix
By agency
NIH$1,298,527 · 4
By mechanism
R43$1,298,527 · 4
Top collaborators
No co-investigators on record.
Others in their field
Other Rising Stars on “Small Business Innovation Research Grant”
- Michael S Mazzola · Louisiana State University$6,764,332
- Farshad Tehrani · Actiox Llc$6,356,284
- Jeff T Hutchins · Inhalon Biopharma, Inc.$6,125,153
- Hyunwoo Yuk · Sanaheal, Inc.$4,709,498
- David Jackson · Ceria Therapeutics, Inc.$4,663,387
- Geaghan Taylor · Icf, Inc., Llc$4,427,444
Research focus
Small Business Innovation Research GrantTranscription FactorPharmaceutical PreparationsScreeningSmall MoleculeTherapeutic TargetCommercializationPathway InteractionsIn SilicoProtein Protein InteractionDrug DevelopmentDna Binding DomainLeadIn VivoCellsBindingGenesFda ApprovedGrantGenetic TranscriptionCytotoxicityInhibitorDna BindingTranslational Impact
Grant awards (4)
The development of a STAT3 inhibitor for lung scleroderma$299,999
R43 · FY2024 · HL · contact PI
Novel STAT3 inhibitor for overcoming chemoresistant ovarian cancer .$399,869
R43 · FY2022 · CA · contact PI
Development of a direct DUX4 inhibitor for Facioscapulohumeral Muscular Dystrophy (FSHD)$299,591
R43 · FY2022 · AR · contact PI
The development of a transcriptional inhibitor for lung fibrosis.$299,068
R43 · FY2022 · HL · contact PI